The DOI matches its Crossref record; 239 of the 239 references it cites were found in a registry or an index.
Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy
Open accessAbstract
OBJECTIVES: To investigate the screening performance of measuring blood pressure and other variables in identifying those who will develop, or die from, ischaemic heart disease and stroke. To quantify by how much drugs that lower blood pressure will reduce the risk of ischaemic heart disease and stroke in those designated 'screen positive'. DATA SOURCES: MEDLINE, Cochrane collaboration and Web of Science databases; Stroke registries; Health Survey for England; Office of National Statistics; BUPA (British United Provident Association) study. REVIEW METHODS: Relevant cohort studies and randomised trials were identified and analysed. Statistical analysis was used to determine drug efficacy and adverse effects. RESULTS: Lowering blood pressure by 5 mmHg diastolic reduces the risk of stroke by an estimated 34% and ischaemic heart disease by 21% from any pre-treatment level; there is no threshold. These estimates, from cohort studies, have been corroborated by the results of randomised trials in persons with high, average and below average levels of blood pressure. In spite of its importance in causing cardiovascular disease blood pressure is a poor predictor of cardiovascular events. Its poor screening performance is illustrated by the findings that in the largest cohort study, persons in the top 10% of the distribution of systolic blood pressure experienced only 21% of all ischaemic heart disease events and 28% of all strokes at a given age. Combining several reversible risk factors adds little to the screening performance of blood pressure alone; for example the 25% of men aged 5564 at highest computed risk (> or =1%) experience only 46% of all ischaemic heart disease events. The main methods of screening should be to identify all persons with a history of cardiovascular disease events (for example identifying patients at the time of hospital discharge following a first myocardial infarction detects 50% of all heart disease deaths in a population at a false positive rate of 12%), and to use a person's age. Identifying everyone with a history of myocardial infarction or stroke in a population and everyone aged 55 or more would include 98% of all deaths from ischaemic heart disease and stroke. The five main categories of blood pressure lowering drugs, thiazides, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin-II receptor antagonists and calcium channel blockers, significantly reduce blood pressure from all pre-treatment levels though the extent of the blood pressure reduction increased with pre-treatment blood pressure. The reductions were similar at standard dose for the five categories; average reduction was 9.1 systolic and 5 diastolic. The effect of combinations of two drugs on blood pressure was additive. No effect of age was apparent, given blood pressure. There were no serious metabolic consequences of using these drugs in standard dose. CONCLUSIONS: The evidence presented indicates that three drugs in combination may reduce stroke by about two-thirds and ischaemic heart disease by half. The report suggests that the term hypertension should be avoided because it is not a disease and it implies another category (normotensives) who would not benefit from lowering blood pressure. Blood pressure reduction using combinations of safe, well-established drugs is effective in preventing cardiovascular events. It is therefore suggested that such preventive therapy be considered more widely in people who by virtue of existing disease or simply age are at risk of a heart attack or stroke regardless of initial blood pressure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Blood pressure, stroke, and coronary heart disease
Collins, R., Peto, R., MacMahon, S., Godwin, J., Qizilbash, N., Collins, R., MacMahon, S., Hebert, P., Eberlein, K. A., Taylor, J. O., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)90944-z · Cited by 4,491
Staessen, J. A., Fagard, R., Thijs, L., Celis, H., Arabidze, G. G., Birkenhäger, W. H., Bulpitt, C. J., de Leeuw, P. W., Dollery, C. T., Fletcher, A. E., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)05381-6 · Cited by 2,989
Cited by
Law, M. R., Morris, J. K., & Wald, N. J. (2009) · BMJ · doi:10.1136/bmj.b1665 · Cited by 2,775
“As the reduction in blood pressure was not reported in most trials of people with a history of CHD, we estimated the average reduction from the average blood pressure before treatment and the average drug dose (as a multiple of standard dose”
BackgroundSelf-citationA strategy to reduce cardiovascular disease by more than 80%
Wald, N. J., & Law, M. R. (2003) · BMJ · doi:10.1136/bmj.326.7404.1419 · Cited by 1,568
Self-citationA Framework for Public Health Action: The Health Impact Pyramid
Frieden, T. R. (2010) · American Journal of Public Health · doi:10.2105/ajph.2009.185652 · Cited by 1,535
Fragala, M. S., Cadore, E. L., Dorgo, S., Izquierdo, M., Kraemer, W. J., Peterson, M. D., & Ryan, E. D. (2019) · Journal of Strength and Conditioning Research · doi:10.1519/jsc.0000000000003230 · Cited by 1,290
Law, M. R., Wald, N. J., Morris, J. K., & Jordan, R. E. (2003) · BMJ · doi:10.1136/bmj.326.7404.1427 · Cited by 1,232
Self-citationFirst-Trimester or Second-Trimester Screening, or Both, for Down's Syndrome
Malone, F. D., Canick, J. A., Ball, R. H., Nyberg, D. A., Comstock, C. H., Bukowski, R., Berkowitz, R. L., Gross, S. J., Dugoff, L., Craigo, S. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043693 · Cited by 1,081
Self-citationWald, D. S., Law, M., Morris, J. K., Bestwick, J. P., & Wald, N. J. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.09.038 · Cited by 938
Self-citationKotseva, K., Wood, D., Backer, G. D., Bacquer, D. D., Pyörälä, K., Keil, U., & EUROASPIRE Study Group (2009) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3283294b1d · Cited by 812
Casas, J. P., Chua, W., Loukogeorgakis, S., Vallance, P., Smeeth, L., Hingorani, A. D., & MacAllister, R. J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67814-2 · Cited by 745
Mazzaglia, G., Ambrosioni, E., Alacqua, M., Filippi, A., Sessa, E., Immordino, V., Borghi, C., Brignoli, O., Caputi, A. P., Cricelli, C., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.830299 · Cited by 637
Atenolol in hypertension: is it a wise choice?
Carlberg, B., Samuelsson, O., & Lindholm, L. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17355-8 · Cited by 562
Toward The ‘Tipping Point’: Decision Aids And Informed Patient Choice
O’Connor, A. M., Wennberg, J. E., Legare, F., Llewellyn-Thomas, H. A., Moulton, B. W., Sepucha, K. R., Sodano, A. G., & King, J. S. (2007) · Health Affairs · doi:10.1377/hlthaff.26.3.716 · Cited by 445
Estimates of benefits and harms of prophylactic use of aspirin in the general population
Cuzick, J., Thorat, M. A., Bosetti, C., Brown, P. H., Burn, J., Cook, N. R., Ford, L. G., Jacobs, E. J., Jankowski, J. A., La Vecchia, C., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu225 · Cited by 382
Self-citationTurning the Pyramid of Prenatal Care
Nicolaides, K. H. (2011) · Fetal Diagnosis and Therapy · doi:10.1159/000324320 · Cited by 357
Risk factor thresholds: their existence under scrutiny
Law, M. R., & Wald, N. J. (2002) · BMJ · doi:10.1136/bmj.324.7353.1570 · Cited by 268
Self-citationThompson, C. S., & Hakim, A. M. (2009) · Stroke · doi:10.1161/strokeaha.108.542266 · Cited by 208
Inorganic nitrite and nitrate: evidence to support consideration as dietary nutrients
Bryan, N. S., & Ivy, J. L. (2015) · Nutrition Research · doi:10.1016/j.nutres.2015.06.001 · Cited by 131
Kaholokula, J. K., Look, M., Mabellos, T., Zhang, G., de Silva, M., Yoshimura, S., Solatorio, C., Wills, T., Seto, T. B., & Sinclair, K. A. (2017) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-015-0198-4 · Cited by 97
Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders
Heal, D. J., Gosden, J., & Smith, S. L. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03549.x · Cited by 86
Nitric oxide deficiency is a primary driver of hypertension
Bryan, N. S. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115325 · Cited by 77
Margolis, K. L., Bergdall, A. R., Crain, A. L., JaKa, M. M., Anderson, J. P., Solberg, L. I., Sperl-Hillen, J., Beran, M., Green, B. B., Haugen, P., et al. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.19816 · Cited by 67
A “green” diet-based approach to cardiovascular health? Is inorganic nitrate the answer?
Rathod, K. S., Velmurugan, S., & Ahluwalia, A. (2016) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201500313 · Cited by 42
Shantharam, S. S., Mahalingam, M., Rasool, A., Reynolds, J. A., Bhuiya, A. R., Satchell, T. D., Chapel, J. M., Hawkins, N. A., Jones, C. D., Jacob, V., et al. (2022) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2021.06.025 · Cited by 13
Metadata
- Authors
- Law, M., Wald, N., & Morris, J.
- Venue
- Health Technology Assessment
- Published
- 2003-11
- Volume
- 7
- Issue
- 31
- Pages
- 1-94
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W2107993459
- Cited by
- 327
- References
- 239
- FWCI
- 5.45
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.